In dental implant clinics, we often hear feedback like this: “With the same implant, others can get their teeth in three months, but I waited half a year and it still had not healed well.” This was a patient who had lived with diabetes for many years. Because his blood glucose control was not ideal, his osseointegration process was significantly delayed, and during the waiting period he was even more worried about infection and failure risks.

Such cases are not isolated. At Arsiokr® , we know well that the implant challenges faced by chronic disease patients are never limited to the technical threshold of “whether implantation is possible.” They also involve full-cycle management of “how to make implantation safer and more reliable.”

Hyperglycemia inhibits osteoblast activity and significantly prolongs the osseointegration period. The longer the healing period, the higher the risk of wound exposure to the oral microbiota. Patients on long-term medication have relatively weakened immune defenses; once inflammation occurs, it subsides more slowly. People with osteoporosis face the problem of insufficient primary stability caused by low bone density—these are clinical pain points we have repeatedly studied since the beginning of product development.

Based on this, Arsiokr®  has built a systematic solution from materials, surface treatment, to structural design:

I. Source Material Selection: Purity First

We use ASTM-certified Grade 4 cold-worked titanium and introduce an ultrasonic post-treatment rinsing process, aiming to thoroughly remove processing agent residues and impurity ions from the implant surface. For chronic disease patients with sensitive constitutions and weaker immunity, this step means fewer postoperative interference factors, allowing healing to return to purity.

II. Ultra-Clean Hydrophilic Surface: Accelerating Osseointegration

HC-SLA ultra-clean hydrophilic surface treatment technology creates a micro-rough structure on the implant surface that favors osteoblast adhesion, while giving the surface superhydrophilic properties that can rapidly adsorb protein components in blood. For groups with poor healing capacity, this helps effectively shorten the osseointegration waiting period and reduce infection risks caused by prolonged wound exposure.

III. Composite Thread Design: Accommodating Diverse Bone Conditions

We have optimized the composite thread structure for the bone characteristics of the Asian population, among whom osteoporosis is highly prevalent, and launched a product line covering diverse diameters and lengths. Even when bone volume is insufficient, it can provide clinicians with more fitting options and improve primary stability.

The following groups may pay particular attention to Arsiokr® :

l Diabetic patients whose blood glucose control requires attention—the hydrophilic surface and ultra-clean process create a more favorable initial environment for osseointegration;

l Patients with osteoporosis or insufficient bone volume—the micro-rough surface and composite thread design help with primary stability;

l Those with slow healing—the hydrophilic surface accelerates protein recruitment, providing effective support for tissue healing;

l Those with high requirements for material biocompatibility—Grade 4 cold-worked titanium + ultrasonic post-treatment, with material purity reaching high standards.

Finally, we solemnly remind you: implant performance is the foundation, but implant success depends more on the patient’s individual bone volume, blood glucose and blood pressure control, and overall health. Any implant decision must be based on a comprehensive preoperative evaluation at a professional medical institution and strictly follow your attending physician’s personalized plan. Good control of underlying diseases is the prerequisite for dental implantation, and scientific selection is key—Arsiokr®  is willing to accompany every chronic disease patient steadily along the implant journey with rigorous craftsmanship.